Posted by Michael Wonder on 12 Nov 2024
Neurotech provides update on BLA for NT-501 as a treatment for macular telangiectasia type 2
8 November 2024 - Neurotech Pharmaceuticals today announced that the US FDA has extended the PDUFA goal date by three months to allow time required for the FDA to review additional data provided by the Company in response to recent requests from the FDA.
The new PDUFA goal date for the biologics license application of NT-501 (revakinagene taroretcel) as a treatment for Macular telangiectasia type 2 is 18 March 2025.
